scholarly journals The Hgfr/Met oncogene is the target for gene amplification in DMBA-induced rat sarcomas

10.1038/87114 ◽  
2001 ◽  
Vol 27 (S4) ◽  
pp. 59-59
Author(s):  
Khalil Helou ◽  
Anna Walentinsson ◽  
Marija Kost-Alimova ◽  
Göran Levan
Keyword(s):  
Gene Amplification ◽  
Met Oncogene

Reevaluation of gene amplification in medulloblastomas

2004 ◽  
Vol 216 (03) ◽  
Author(s):  
T Lenschen ◽  
J Mühlisch ◽  
H Jürgens ◽  
C Plass ◽  
D Smiraglia ◽  
...  
Keyword(s):  
Gene Amplification

HER-2 gene amplification in pancreatic cancer

2004 ◽  
Vol 42 (05) ◽  
Author(s):  
K Borka ◽  
A Kiss ◽  
A Tőkés ◽  
P Kaliszky ◽  
P Kupcsulik ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Gene Amplification ◽  
Her 2

A PILOT STUDY OF HER-2/NEU GENE AMPLIFICATION ASSESSED BY FLUORESCENCE IN SITU HYBRIDIZATION (FISH) IN GASTRIC CANCER

2014 ◽  
pp. 15-20
Author(s):  
Van Huy Tran ◽  
Thi Minh Thi Ha ◽  
Trung Nghia Van ◽  
Viet Nhan Nguyen ◽  
Phan Tuong Quynh Le ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
In Situ Hybridization ◽  
Fluorescence In Situ Hybridization ◽  
Cancer Patients ◽  
Gene Amplification ◽  
Cancer Tissue ◽  
Tissue Samples ◽  
Her 2 ◽  
Gastric Cancer Patients

Background: HER-2/neu is a predictive biomarker for treatment of gastric cancer using trastuzumab in combination with chemotherapy. This study aimed to evaluate the status of HER-2/neu gene amplification using fluorescence in situ hybridization (FISH) in gastric cancer. Patients and methods: thirty six gastric cancer patients were assessed HER-2/neu gene amplification by FISH using PathVysionTM HER-2 DNA Probe kit (including HER-2/neu probe and CEP-17 probe) with biopsy and surgical specimens. Results: The HER-2/neu gene amplification was observed in three cases (8.3%), the HER-2/neu gene amplification rate in Lauren’s intestinal-type and diffuse-type were 11.8% and 5.2%, respectively. Conclusion: We applied successfully FISH technique with gastric cancer tissue samples. This technique could be performed as routine test in gastric cancer in order to select patients that benefit from trastuzumab in combination with chemotherapy.

scholarly journals Clinicopathological features and differential diagnosis of gastrofibromatosis-like undifferentiated carcinoma

2020 ◽  
Vol 48 (12) ◽  
pp. 030006052097446
Author(s):  
Zhishang Zhang ◽  
Guang Zhao ◽  
Bo Jiang ◽  
Baohui Li ◽  
Yangkun Wang
Keyword(s):  
Differential Diagnosis ◽  
Gene Amplification ◽  
Smooth Muscle Actin ◽  
Growth Factor Receptor ◽  
Aggressive Fibromatosis ◽  
Undifferentiated Carcinoma ◽  
Clinicopathological Features ◽  
Gastric Body ◽  
Her2 Gene ◽  
Her2 Gene Amplification

Objective To study the clinicopathological features and differential diagnosis of gastrofibromatosis-like undifferentiated carcinoma (GFLUC). Methods Three patients with GFLUC underwent histological and immunophenotypic analyses and fluorescence in situ hybridization to detect human epidermal growth factor receptor ( HER2) gene amplification. Results Among the three patients (2 male [36 and 44 years old], 1 female [58 years old]), two had lesions in the gastric body and one had lesions in the gastric antrum. Histological analysis revealed mixtures of aggressive fibromatosis and undifferentiated carcinoma in all three cases. Highly invasive fibromatous tissue, consisting of fibroblasts, proliferating myofibroblasts, and collagenous fibrous tissues, accounted for >90% of the tumor, with undifferentiated cancerous tissue accounting for <10% scattered in the gaps within the invasive fibromatous tissue, with no glandular ducts or nests. Immunophenotypic analysis showed that the undifferentiated cancerous cells were positive for pan-cytokeratin, CDX2, villin, and p53, while the cytoplasm of invasive fibromatous cells was positive for vimentin, β-catenin, and smooth muscle actin. No HER2 gene amplification was detected. Conclusions Unlike other gastric carcinomas, GFLUC shows specific histological, biological, and immunophenotypic characteristics.

Sign in / Sign up

Export Citation Format

Share Document